Sequential enfortumab vedotin (EV) after platinum-based chemotherapy in metastatic or locally advanced urothelial cancer: Complete response, bladder preservation and survival.

被引：0
|
作者：
Cen, Putao
Chan, Kok Hoe
Canfield, Steven
Shu, Tung
Maithel, Neha
Tammisetti, Varaha
机构：
[1] Univ Texas Hlth Sci Ctr Houston UTHealth Houston, McGovern Med Sch, Houston, TX USA
[2] Univ Texas Med Sch Houston, Houston, TX USA
[3] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
    van der Heijden, M. S.
    Gupta, S.
    Galsky, M. D.
    Derleth, C.
    Steinberg, J.
    Kataria, R.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S605 - S606
  • [32] EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Powles, T. B.
    Van der Heijden, M. S.
    Gupta, S.
    Perez Valderrama, B.
    Galsky, M. D.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Rey, J. P. Maroto
    Vulsteke, C.
    Iyer, G.
    Swami, U.
    Shin, S. J.
    Rodriguez-Vida, A.
    Wozniak, M.
    Moreno, B. Homet
    Lu, J.
    Yu, C.
    Hogdal, L.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1137 - S1138
  • [33] Real world progression-free survival in patients with advanced or metastatic urothelial cancer treated with first-line platinum-based chemotherapy
    Nikolaidis, Christos
    Li, Chen
    Lee, Chooi
    Mecke, Almut
    Reyes-Rivera, Irmarie
    Schroder, Carsten
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 319 - 319
  • [34] EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy.
    Petrylak, Daniel
    Rosenberg, Jonathan
    Duran, Ignacio
    Loriot, Yohann
    Sonpavde, Guru
    Wu, Chunzhang
    Gartner, Elaina
    Melhem-Bertrandt, Amal
    Powles, Thomas
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 59 - 60
  • [35] Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy
    Gurney, Howard
    Mamtani, Ronac
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Bedke, Jens
    van der Heijden, Michiel
    Wu Chunzhang
    Hepp, Zsolt
    McKay, Caroline
    Petrylak, Daniel P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 66 - 67
  • [36] DO MIXED HISTOLOGICAL FEATURES AFFECT SURVIVAL BENEFIT FROM NEOADJUVANT PLATINUM-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER?
    Balarand, Arjun V.
    Milowsky, Matthew I.
    BJU INTERNATIONAL, 2011, 108 (05) : 699 - 699
  • [37] Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
    McGregor, B. A.
    O'Donnell, P. H.
    Balar, A.
    Petrylak, D. P.
    Rosenberg, J. E.
    Yu, E.
    Quinn, D. I.
    Shah, S. N.
    Pinelli, J.
    Hepp, Z.
    Galsky, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] Editorial Comment to Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer
    Gauthier, Helene
    Culine, Stephane
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (05) : 495 - 495
  • [39] Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer
    Yuasa, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (09) : 975 - 975
  • [40] First-line Maintenance Therapy in adult Patients with locally advanced or metastatic Urothelial Carcinoma who are progression-free after platinum-based Chemotherapy
    Rexer, Heidrun
    Gschwend, Jurgen
    Merseburger, Axel S.
    AKTUELLE UROLOGIE, 2024, 55 (04) : 297 - 298
12345